Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Ashiya, HyogoFounded 1975937 employeesWebsite
A research-driven pharmaceutical company with expertise in rare diseases. It focuses on developing biopharmaceuticals, including those using its proprietary blood-brain barrier technology.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Pharmaceutical Business | 100% | ¥40.3B | ¥555M | 1.4% |
Close (Oct 30, 2026)
¥544-5.7% (1Y)
JCR -5.7% over 1Y, 19.1pt below the industry average (23 companies, +13.4%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥40.3B | ¥555M | ¥2.2B | ¥109.2B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jan 2026)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
